ORPHA:90045
Hereditary folate malabsorption
Also known as: Congenital folate malabsorption
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
892
Trials
0
Interventional, condition-specific
Researchers
782
Distinct authors in sample
Gene link
SLC46A1
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
folate malabsorption (HFM) is an inherited disorder of folate transport characterized by a systemic and central nervous system (CNS) folate deficiency manifesting as megaloblastic anemia, , diarrhea and/or oral mucositis, immunologic dysfunction and neurological disorders.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009238
- MeSH:C562799
- OMIM:229050
- UMLS:C0342705
- NCIT:C156424
Additional Mondo synonyms (1)
congenital folate malabsorption
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — SLC46A1
- LiteraturePresent
892 matched papers (588 in last 10 years) Source
- Phenotype characterisedPresent
48 HPO annotations (e.g. Recurrent urinary tract infections; Glossitis; Global developmental delay) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (SLC46A1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
48
Associated phenotypes · MONDO:0009238
- Recurrent urinary tract infections
- Glossitis
- Global developmental delay
- Hyperreflexia
- Failure to thrive
Showing 5 of 48 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
892
892 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
892 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
588 in the last 10 years · low confidence
Phrase hits: 217 · MeSH hits: 0
Who's working on it?
782
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Goldman ID47 papers · 2025
Department of Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, United States; Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, United States. Electronic address: i.david.goldman@einstein.yu.edu.
Papers in Europe PMC - 02Zhao R40 papers · 2020
Departments of Medicine, Albert Einstein College of Medicine, Chanin 628, 1300 Morris Park Ave, Bronx, NY, 10461, USA, rongbao.zhao@einstein.yu.edu.
Papers in Europe PMC - 03Fiser A15 papers · 2025
Department of Systems and Computational Biology, Albert Einstein College of Medicine, Bronx, NY 10461, United States; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, United States.
Papers in Europe PMC - 04Matherly LH14 papers · 2022
Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, U.S.A. Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, U.S.A. Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201, U.S.A.
Papers in Europe PMC - 05Hou Z12 papers · 2022
Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, U.S.A. Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, U.S.A.
Papers in Europe PMC - 06Shin DS10 papers · 2019
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
Papers in Europe PMC - 07Diop-Bove N9 papers · 2014
Department of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA.
Papers in Europe PMC - 08Aluri S8 papers · 2020
Department of Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, United States; Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, United States.
Papers in Europe PMC - 09Finnell RH8 papers · 2022
Departments of Molecular and Cellular Biology and Medicine, Baylor College of Medicine , Houston, Texas 77030, United States.
Papers in Europe PMC - 10Visentin M8 papers · 2019
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Hereditary folate malabsorption — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Hereditary folate malabsorption" OR "Congenital folate malabsorption") OR (MESH:"Folate Malabsorption, Hereditary") OR ("SLC46A1" OR "SLC46A1 syndrome" OR "SLC46A1-related")MeSH descriptor terms unioned into the query: Folate Malabsorption, Hereditary
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Hereditary folate malabsorption" OR "Congenital folate malabsorption" OR "Folate Malabsorption, Hereditary"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (892) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T03:31:47.307Z